Pacgen Provides Update on Licensed Product, PAC-113

VANCOUVER, BRITISH COLUMBIA--(Marketwired - June 11, 2015) - Pacgen Life Science Corporation ("Pacgen" or the "Company") (TSX VENTURE:PBS) disclosed today that its licensing partner, General Biologicals Corporation ("GBC"), has announced acceptance of abstract entitled "P113-derived peptides as novel inhibitors for drug resistant Candida spp" at the 6^thCongress of European Microbiologist ("FEMS 2015") held in Maastricht, Netherlands. The abstract highlights findings of a research study conducted by Institute of Molecular and Cellular Biology and Department of Life Sciences of National Tsing Hua University, Taiwan in collaboration with GBC.

The Company also disclosed that GBC has launched non-prescription over-the-counter ("OTC") products containing PAC-113 in Taiwan including cosmetic skin-care products, oral hygiene products and intimate hygiene products. These non-prescription OTC products can be purchased on-line at www.p113lab.com and several local stores in Taiwan. GBC plans to formally launch these products through its existing global distribution channels in July 2015.

About Pacgen

Pacgen is a life science technology company focused on the commercialization of biomedical products and services, including its previous development of novel therapeutic drug candidates. For additional information, please visit www.pacgenlife.com.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward looking Statements

Certain statements included in this press release may be considered forward-looking. Statements relating to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments constitute forward-looking statements. All forward-looking statements are based on Pacgen's current beliefs and expectations as well as assumptions relating to the successful completion of its clinical trials and pre-clinical studies, the time and process required to obtain regulatory approval for commercialization of its product, the ability of Pacgen to raise additional capital in future on favourable terms, the impact of competitive products and pricing in the market, new product development, and the successful and timely completion of corporate collaborations or licensing arrangements for its research programs. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, level of activity, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with completion of clinical trials and obtaining regulatory approval, dependence on collaborative partners, and our ability to protect our intellectual property.

Wherever possible, words such as "anticipate", "believe", "expect", "may", "could", "will", "potential", "intend", "estimate", "should", "plan", "predict", "project" or the negative or other variations of such expressions reflect Pacgen's current beliefs and assumptions and are based on the information currently available to Pacgen. Certain risks and uncertainties, including those risk factors identified by Pacgen in its annual management's discussion and analysis dated July 28, 2014, may cause our actual results, level of activity, performance or achievements to differ materially from those implied by forward looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. Pacgen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For all forward-looking statements, Pacgen claims the safe harbour for forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.